Week in Review: FDA Revokes Emergency Use Authorizations for Chloroquine, Hydroxycholoroquine

Top news of the week from Pharmacy Times®.

5. FDA Revokes Emergency Use Authorization for Chloroquine, Hydroxychloroquine

The FDA has announced the end of the emergency use authorizations for oral formulations of chloroquine phosphate and hydroxychloroquine sulfate, saying the potential benefits do not outweigh its known risks. Read more.

4. Immunization Administration During Coronavirus Disease Pandemic

The rapid spread and manner of transmission of the SARS-CoV-2 virus, and decreased availability of personal protective equipment, present a challenge to safe administration of immunizations in a community pharmacy setting. Read more.

3. FDA Approves Dolutegravir for Infants, Children with HIV

Dolutegravir tablets are intended to treat pediatric patients at least 4 weeks old and at least 6 pounds who have never been treated for HIV or who have been treated, but not with an integrase strand transferase inhibitor class drug. Read more.

2. FDA Approves FreeStyle Libre 2 iCGM System for Patients With Diabetes

The FDA granted approval to Abbott’s FreeStyle Libre 2 integrated continuous glucose monitoring system for adults and children ages 4 and older with diabetes. Read more.

1. Get Familiar with the FDA Drug Recall Process

On average, 4500 drugs and medical devices are pulled from shelves across the United States each year because of product recalls, so pharmacists should be familiar with the FDA drug recall process. Read here.